摘要
对1例Bismuth分型为Ⅳ型且合并肝门部及胰头后淋巴结转移的肝门部胆管癌患者,施行肝、胰头十二指肠联合切除并原位肝移植。移植后初期采用激素、FK506及骁悉三联免疫抑制治疗,激素用量较常规小并迅速撤除。对早期肝功能及胰腺功能情况作了连续观察,并对肿瘤标志物CA19-9作了对比观察。移植后病理报告为中、低分化性肝门部胆管癌侵犯左、右肝管并肝方叶,肝门部及胰头后淋巴结有转移,胰头、十二指肠及切除之部分胃未见癌侵犯。患者移植肝功能恢复顺利,胰腺内、外分泌功能保持良好。CA19-9降至正常。移植后1个月患者痊愈出院。现患者已存活10个月,未发现肿瘤复发迹象。作者认为,肝、胰头十二指肠联合切除并肝移植治疗肝门部胆管癌是安全可行的。
One patient of Ⅳ type hilar cholangiocarcinoma with neck lymph node metastasis was underwent pancreaticoduodenectomy and liver transplantation. Low dose of hormone, FK506 and triple immunosuppressive therapy was performed following transplantation. Hepatic and pancreatic function was continuous observed, and contrast observation performed at tumor markers of CA19-9. The pathological report showed that cholangiocarcinoma had infringement left and right hepatic duct as well as Iobus quadratus hepatis, lymph node of hilar and head of pancreas were metastasized, but the resection part of stomach and duodenum showed no carcinoma invading. After transplantation, the function of transplanted liver recovered smoothly, secretion function of pancreas remains well, and tumor markers of CA19-9 decreased to a normal level. The patient survived for 10 months without tumor recurrence. The result revealed that it is safe and feasible to treat with hilar cholangiocarcinoma combined pancreaticoduodenectomy and liver transplantation.
出处
《中国组织工程研究与临床康复》
CAS
CSCD
北大核心
2009年第18期3577-3579,共3页
Journal of Clinical Rehabilitative Tissue Engineering Research
